CytomX Therapeutics (CTMX) Wells Fargo 21st Annual Healthcare Conference summary

Key program and clinical updates

• Varseta-M, an EpCAM-targeting masked ADC, is advancing in late-line colorectal cancer with FDA Fast Track designation and promising clinical data, including significant response rates and a favorable safety profile.

• Dose optimization and combination studies with bevacizumab and chemotherapy are ongoing, with plans to initiate the first pivotal or registrational study in the first half of next year and expand into earlier lines and additional tumor types such as gastric, pancreatic, biliary tract, GEJ, and PDAC cancers.

• The program aims for broad applicability, potentially reaching a pan-tumor label due to high EpCAM expression across multiple cancers, with expansion studies enrolling about 60 patients across three tumor types.

• Multiple clinical milestones are anticipated in the next 12–18 months, including updated phase I data, study initiations, and strategic plans for registrational studies.

• CX-801, a masked Interferon alfa-2b, is in phase I for late-line melanoma, aiming to reactivate immune response in patients who have progressed after dual checkpoint therapy, with combination studies with KEYTRUDA underway and initial data expected in the first half of next year.

Technology, strategy, and market insights

• The proprietary Probody platform enables selective activation of therapeutics within tumor tissue, minimizing systemic toxicity and unlocking previously undruggable targets like EpCAM.

• Varseta-M uses a novel topoisomerase I inhibitor payload (masetecan) linked via a cleavable peptide, designed for high efficacy in CRC.

• The approach allows treatment of all-comer patient populations without biomarker selection, streamlining enrollment and broadening potential impact.

• Colorectal cancer remains a major unmet need, with incidence projected to reach 3 million globally by 2040 and a 5-year survival rate of 13% in mCRC; Varseta-M targets a large addressable market, with over 90,000 U.S. patients in 1L mCRC and a total addressable market exceeding $30 billion.

• Financially, the organization reported $330M in cash as of Q2 2026, with additional funding from partnerships and a runway extending into the second half of 2028.

Competitive landscape and differentiation

• Varseta-M is positioned as a potential first-in-class ADC for EpCAM+ tumors, with a differentiated safety and efficacy profile compared to current late-line mCRC therapies.

• Current standard-of-care therapies in 3L+ mCRC offer limited survival benefits, highlighting the need for novel approaches.

• The development strategy includes both monotherapy and combination regimens to address diverse patient populations and treatment settings.

• CX-801’s dual-masking technology aims to enhance tolerability and efficacy in immunotherapy-resistant melanoma, offering a novel combination approach with checkpoint inhibitors.

• The pipeline is designed to address high unmet needs in oncology, with a focus on expanding into additional solid tumor indications.